A phase 1 randomized, placebo-controlled, single ascending dose study to examine the safety, tolerability, and pharmacokinetics of CNP8 in healthy adults
Active Project Grant Awarded Last action
- Award ID
- HT94252311064
- Recipient
-
Neomatrix Therapeutics Inc. UEI Z9ZTKJPE92R4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $2,199,979
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 79% complete
- Originally
- Place of performance
- Stony Brook, NY 11790, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $2,199,979 |
Quick answers
Who received award HT94252311064?
HT94252311064 was awarded to Neomatrix Therapeutics Inc. by Defense Health Agency (Department of Defense) on September 22, 2023.
How much is award HT94252311064 worth?
$2,199,979 has been obligated on HT94252311064.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award